Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PureTech Health plc - American Depositary Shares (NQ:PRTC)

16.07 +0.25 (+1.61%)
Streaming Delayed Price Updated: 10:05 AM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,689
Open 16.07
Bid (Size) 6.660 (200)
Ask (Size) 19.07 (100)
Prev. Close 15.82
Today's Range 16.07 - 16.07
52wk Range 13.30 - 24.99
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting
From PureTech Health plc
Via Business Wire
News headline image
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
From PureTech Health plc
Via Business Wire

Performance

YTD
-17.5%
-17.5%
1 Month
-11.6%
-11.6%
3 Month
-12.4%
-12.4%
6 Month
-10.2%
-10.2%
1 Year
-24.4%
-24.4%

More News

Read More
News headline image
Earnings Scheduled For April 30, 2025 ↗
Via Benzinga
News headline image
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
From PureTech Health plc
Via Business Wire
News headline image
CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday ↗
Via Benzinga
News headline image
PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
From PureTech Health plc
Via Business Wire
News headline image
PureTech (PRTC) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
PureTech Health Cash Runway Extended ↗
Via The Motley Fool
News headline image
Earnings Scheduled For August 28, 2025 ↗
Via Benzinga
News headline image
PureTech Health plc – Half-Year Report
From PureTech Health plc
Via Business Wire
News headline image
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
From PureTech Health plc
Via Business Wire
News headline image
PureTech Health: Notice of Half-Yearly Results
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Leadership Transition
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Board Change
From PureTech Health plc
Via Business Wire
News headline image
Why This Biotech Stock Just Doubled In A Single Day ↗
Via Benzinga
News headline image
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
From PureTech Health plc
Via Business Wire
News headline image
PureTech Health: Results of Annual General Meeting
From PureTech Health plc
Via Business Wire
News headline image
PureTech to Present at the Jefferies Global Healthcare Conference
From PureTech Health plc
Via Business Wire
News headline image
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
From PureTech
Via Business Wire
News headline image
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
From PureTech Health plc
Via Business Wire
News headline image
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Annual Results for Year Ended December 31, 2024
From PureTech Health plc
Via Business Wire

Frequently Asked Questions

Is PureTech Health plc - American Depositary Shares publicly traded?
Yes, PureTech Health plc - American Depositary Shares is publicly traded.
What exchange does PureTech Health plc - American Depositary Shares trade on?
PureTech Health plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for PureTech Health plc - American Depositary Shares?
The ticker symbol for PureTech Health plc - American Depositary Shares is PRTC on the Nasdaq Stock Market
What is the current price of PureTech Health plc - American Depositary Shares?
The current price of PureTech Health plc - American Depositary Shares is 16.07
When was PureTech Health plc - American Depositary Shares last traded?
The last trade of PureTech Health plc - American Depositary Shares was at 11/20/25 10:05 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.